Cylin

Quick links to important sections

Cylin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cylin

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Oral Tablets, Oral Syrup (Solution)
Pharmacological Class First-Generation Antihistamine, H1-Receptor Antagonist
General Purpose Relieves symptoms related to allergic reactions and hypersensitivity
Origin Synthetic, Piperidine derivative

What is Cylin and What Type of Drug is it?

Cylin is a medication whose active component is Cyproheptadine hydrochloride, classified pharmacologically as a First-Generation Antihistamine and an H1-Receptor Antagonist. This means its primary function is to block the actions of histamine, a natural compound that triggers the body's allergic responses.

The active substance Cyproheptadine is a synthetic Piperidine derivative, distinguishing it from newer second-generation antihistamines through its molecular structure. This first-generation classification reflects its dual functionality: beyond being a primary antihistamine, it also functions as an antiserotonergic agent, blocking certain serotonin receptors. The drug's chemical properties result in an inherent sedative effect due to its ability to cross the blood-brain barrier.


Composition and Available Forms of Cyproheptadine

The medicine is formulated as a single-ingredient product, containing only the therapeutic substance Cyproheptadine in the form of its hydrochloride sesquihydrate salt. For patient use, Cylin is available in two main dosage form(s): solid tablets and a liquid oral syrup (or solution).

Both forms are designed for the oral route of administration, allowing the standardized amount of Cyproheptadine to be absorbed through the digestive system. The availability of both the tablets and the liquid oral syrup ensures flexibility for diverse patient groups who may require an alternative to the tablet form.


General Purpose and Core Action of First-Generation Antihistamines

The general purpose of the medication is to provide relief by stabilizing the body's reaction to allergens through its fundamental histamine blocking principle. This core action helps to mitigate the overall discomfort and physical symptoms associated with general hypersensitivity states.

The medication works as a competitive antagonist, effectively occupying and neutralizing the receptors that histamine would normally activate, thereby preventing the chemical cascade that leads to allergic irritation and discharge. Its classification and mechanism define its overall scope: helping to lessen the physical consequences of the body's internal fight against allergens.

What side effects are possible with Cylin?

Possible side effects and safety information

The safety profile of Cyproheptadine hydrochloride, a first-generation antihistamine, is defined by its primary effects on the Central Nervous System (CNS) and its anticholinergic properties, as documented in official regulatory labeling.


Frequency and System-Organ Effects

The most frequently reported adverse reaction is drowsiness, often classified as a very common effect. This sedation is noted to be most prominent at the start of treatment and may lessen with continued administration. Other effects on the Nervous System include dizziness, disturbed coordination, and fatigue. In some individuals, particularly pediatric patients, the response may be paradoxical, leading to excitement or irritability.

Due to its mechanism, the medication can cause Anticholinergic Effects, which typically include dry mouth, blurred vision, and sometimes urinary retention. Effects on the Gastrointestinal System include nausea, constipation, and an officially noted potential for increased appetite and subsequent weight gain.


Serious Reactions and Safety Constraints

Official labels document rare but serious adverse reactions that affect the body's systems, including blood dyscrasias (such as leukopenia or agranulocytosis) and hepatitis (liver dysfunction). Convulsions and severe hypersensitivity responses are also documented as rare serious events.

Specific population safety considerations are outlined: the medication is contraindicated in newborns and premature infants. Older adults may be more susceptible to the sedating effects and anticholinergic consequences. High-level safety constraints include contraindications for individuals with narrow-angle glaucoma, stenosing peptic ulcer, and severe hepatic impairment.

Overdose and Emergency Response

Cylin Overdose and when to seek help

Overdose with Cyproheptadine hydrochloride is associated with severe, potentially life-threatening systemic manifestations documented in regulatory sources. Clinical presentations may vary widely, ranging from profound Central Nervous System (CNS) depression, characterized by excessive drowsiness and coma, to CNS stimulation, which may involve hallucinations, agitation, and convulsions (seizures). Official labeling also describes anticholinergic signs, such as mydriasis (dilated pupils), dry mouth, fever, and tachycardia (rapid heartbeat).

The documentation identifies severe cardiovascular and respiratory complications, including serious heart rhythm disturbances, respiratory arrest, cardiac arrest, and death as potential outcomes. Overdose poses a particularly high risk in infants and young children due to their increased vulnerability to severe CNS and cardiorespiratory events.

Immediate medical care is mandated when overdose is suspected. Urgent help must be sought if life-threatening signs such as a seizure, severe trouble breathing, or the patient’s inability to be awakened are observed. Management is defined as symptomatic and supportive treatment, often involving procedures like gastric lavage and the administration of activated charcoal; no specific antidote is known.

Therapeutic Uses of Cylin

Cylin is generally used across conditions presenting with systemic or localized discomfort. This application may assist with maintaining functional stability in relevant contexts.

The medication is commonly used to help with managing symptoms related to inflammatory or irritative states, such as those arising from allergic rhinitis (seasonal and perennial), allergic conjunctivitis, and certain skin conditions like hives (urticaria) and angioedema. It also may be part of symptomatic management for promoting appetite stimulation and may be used to assist with the symptomatic management of recurrent vascular headaches (migraine prophylaxis).

Quick Fact: Symptomatic Easing in Pruritus and Nasal Domains

Cylin is considered relevant for managing symptom clusters that may become intense or disruptive, especially persistent itching and the classic upper respiratory signs of allergic reactions, like sneezing and rhinorrhea. This may provide supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The use of Cylin (Cyproheptadine) is generally indicated for individuals treating allergic conditions (such as seasonal or perennial allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis) or for those requiring appetite stimulation to manage undernutrition or weight loss.

However, certain medical conditions and demographics pose significant contraindications or necessitate careful medical review. Patients should not use Cylin if they have a known hypersensitivity or allergic reaction to cyproheptadine or structurally similar drugs.


Contraindications and Cautions

Do Not Use Cylin Use With Extreme Caution
Angle-closure glaucoma Elderly patients, especially those with cognitive impairment
History of peptic ulcers Patients with a history of asthma or other respiratory issues
Urinary retention or bladder neck obstruction Existing liver or kidney impairment
Concomitant use with Monoamine Oxidase (MAO) inhibitors Pregnant or breastfeeding individuals
Newborns or premature infants Patients with cardiovascular disease (e.g., hypertension, tachycardia)

It is essential to inform a healthcare provider of any existing medical conditions, all current medications, and any plans for pregnancy or breastfeeding before beginning treatment with Cylin. Its sedative effects mean patients should avoid driving or operating heavy machinery until they understand the medication's full impact.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cylin, whose active ingredient is Cyproheptadine hydrochloride, has documented interaction patterns based on its classification as a First-Generation Antihistamine with significant anticholinergic and antiserotonergic properties, as noted in official regulatory labeling.

Official Regulatory Interaction Profile

Interaction Type Interacting Substances/Classes Restriction Status
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Prohibited (Prolongs and intensifies anticholinergic effects)
Pharmacodynamic Interaction Central Nervous System (CNS) Depressants, Alcohol Additive Risk (Increased CNS depression)
Pharmacodynamic Interference Serotonin-enhancing Antidepressants (e.g., SSRIs) May interfere with antidepressant effect
Population Constraint Elderly or Debilitated Patients Contraindicated (Increased risk of dizziness and sedation)
Procedural Note Tricyclic Antidepressants (TCAs) May cause false positive test result

Co-administration with Monoamine Oxidase Inhibitors is strictly prohibited according to regulatory labeling. Caution is necessary when using Cylin alongside alcohol and other substances classified as CNS depressants, which include various sedatives, tranquilizers, and hypnotics, due to the risk of additive effects. Additionally, its anti-serotonin activity may interfere with the intended action of certain serotonin-enhancing antidepressants. Official labeling also contraindicates use in elderly or debilitated patients due to their increased susceptibility to certain additive effects.

Mechanism of Action

Cylin, a macrocyclic inhibitor, targets and modulates intracellular protein-to-protein interactions involving Cyclin A and Cyclin B. The drug selectively acts as an inhibitor by directly binding to the RxL motif binding pocket on Cyclin A and Cyclin B, preventing the assembly of functional protein complexes.

Specifically, the primary molecular pathway involves the disruption of the Cyclin A-E2F interaction and the Cyclin B-Myt1 interaction. Downstream consequences of blocking the Cyclin A-E2F axis include the aberrant and sustained accumulation of E2F activity, which initiates DNA damage and replication stress. The concurrent inhibition of the Cyclin B-Myt1 complex removes a critical regulatory checkpoint, effectively preventing the cell from arresting in response to the damage. This dual action forces the damaged cell to proceed into an unviable mitosis, resulting in mitotic catastrophe and consequent programmed cellular demise. The system-level physiological consequence is the targeted cessation of cell proliferation in tissues characterized by dysregulated cell cycle control and high E2F activity.

Dosage and Administration Information

Official Administration Guidelines for Cylin (Clindamycin Oral)

These instructions are based on prescribing information and official monographs, outlining the required steps for proper use.


Administration Scope

Feature Official Requirement
Route of Administration Oral (by mouth)
Standard Adult Dose Typically 150 mg to 450 mg per dose, depending on severity of condition.
Frequency Must be taken three or four times a day at evenly spaced intervals.
Food Relationship Can be taken with or without food, but must be taken with a full glass of water (6 to 8 ounces).
Capsule Condition Capsules must be swallowed whole; they must not be chewed, crushed, or opened.
Post-Dose Requirement The patient must remain upright (sitting or standing) for at least 30 minutes after taking the capsule.

Procedural Structure and Consistency

Adherence to the schedule and technique is essential for effective use. If a dose is missed, take it as soon as remembered; however, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose. The full prescribed course of medication must be completed, even if symptoms improve early, unless otherwise directed by a healthcare professional. Dosing for pediatric patients is typically calculated based on body weight.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cylin


Evidence for Use in Allergic Rhinitis and Pruritus

Cylin (Cyproheptadine) was studied for its use in conditions involving periods of heightened symptoms such as allergic rhinitis (seasonal or perennial) and persistent pruritus (itching). The research exploring how symptoms change over time for these indications primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews of these trials. These studies examined outcomes related to physical discomfort, such as the severity of sneezing, a runny nose (rhinorrhea), and eye irritation.

Findings describe group patterns observed in the studies, where measurements of outcomes related to physical discomfort were collected when compared to a placebo or other first-generation antihistamine agents. This evidence contributes to the broader evidence landscape for conditions linked to inflammatory or irritative states. What remains uncertain is how Cyproheptadine compares to newer, second-generation antihistamines in research studies, as recent large-scale research exploring this specific comparison is limited.


Evidence for Use in Appetite Stimulation and Weight Changes

Research has explored Cyproheptadine's secondary application regarding appetite and body weight changes. The studies examining these outcomes related to systemic or functional imbalance include smaller RCTs and prospective and retrospective cohort studies. These studies monitored anthropometric measurements, such as changes in body weight or Body Mass Index (BMI).

Findings from these studies report how symptoms evolved in the observed populations, specifically documenting weight and BMI changes over defined time intervals, typically ranging from a few weeks to a few months. The research was predominantly focused on pediatric populations, including children with undernutrition or poor weight gain associated with various chronic health conditions.

The research exploring this application has specific limitations. The evidence quality varies across studies due to the heterogeneous nature of the studied cohorts. The specific reasons behind the reported changes in weight were not a primary outcome of the studies and are not fully established within the research findings.


Evidence for Use in Migraine Prophylaxis

Cyproheptadine was studied for its use in conditions characterized by fluctuating or episodic manifestations, specifically the outcomes related to the prevention of recurrent vascular headaches (migraines). The evidence base for research in this area is generally considered limited. It largely consists of historical, small-scale RCTs and retrospective analyses, where researchers examined outcomes describing episodic or acute changes, such as the frequency of headaches per month. Studies report how symptoms evolved in the observed populations related to headache frequency measurements, but findings were mixed across the published literature.

Key Studies & References Cyproheptadine, MedlinePlus Drug Information (Application Context)

Frequently Asked Questions (FAQ)

Common questions about Cylin (FAQ)


Q: Is Cylin considered a short-term or long-term medication?

Regulatory documents indicate that clinical trials for Cylin primarily focused on short-term use, often spanning a few weeks to a few months for its approved indications. Official labels contain limited data on the effects or safety of its use over extended periods. The duration of use is determined based on the patient's medical needs.


Q: How quickly can someone expect to feel the effects of Cylin?

As a first-generation antihistamine, the effects of Cylin are generally expected to begin relatively soon after administration. For some conditions, historical data suggest that relief may be observed relatively soon after administration. The time to full therapeutic effect is variable.


Q: Does Cylin have any major warnings listed by the FDA or other regulators?

Yes, official regulatory documents list several Contraindications and Warnings. For example, the drug is prohibited for use with medications called Monoamine Oxidase Inhibitors (MAOIs). Caution is also advised for use in older patients and for individuals with certain pre-existing conditions like narrow-angle glaucoma or certain types of ulcers. This information helps guide appropriate patient selection.


Q: Can Cylin be used in children or adolescents?

Official product information states that Cylin can be used in children age 2 years and older for certain conditions, with dosing calculated based on body weight. It is specifically contraindicated (should not be used) in newborns and premature infants. Safety and effectiveness have not been established for children younger than 2 years of age.


Q: Does Cylin affect the kidneys or liver?

Regulatory documents list severe hepatic impairment (a serious liver issue) as a reason the drug should not be used. Official labels also advise that caution should be exercised when Cylin is used in patients who have existing kidney impairment. This information helps guide appropriate patient selection.


Q: Are there generic versions of Cylin available?

Yes, the active ingredient in Cylin, which is Cyproheptadine hydrochloride, is widely available in generic formulations. This means generic formulations in various forms (such as tablets and oral syrup) are available.


Q: Is the research evidence for Cylin considered strong?

The evidence base includes various studies, such as short-term randomized controlled trials for allergic conditions. Official overviews note that the evidence quality for certain secondary uses, like appetite stimulation, can be variable and limited across different study groups. The certainty of findings varies depending on the specific use examined.


Q: Does Cylin cause weight gain or weight loss?

Official labeling documents that an increased appetite is a documented adverse effect of the medication. Subsequent weight gain is a reported outcome found in clinical studies, particularly in the appetite stimulation setting. Weight loss is not a stated adverse reaction in official product information.


Q: Do Cylin side effects usually improve over time?

Regulatory information specifically states that the most common adverse reaction, drowsiness or sedation, is often most noticeable when treatment begins but may lessen with continued administration. This documentation of improvement over time is specific to drowsiness and is not stated for all other potential side effects.


Q: What information is available about Cylin in long-term safety studies?

Official regulatory documents indicate that long-term carcinogenic studies (tests to see if a drug causes cancer) have not been done with Cyproheptadine. Although long-term animal toxicity studies have been performed, the regulatory label does not contain a comprehensive summary of long-term human safety.


Q: Can Cylin be taken with a multivitamin?

Official regulatory labeling does not document any specific interactions between Cylin and standard multivitamin formulations. Some research has examined the use of Cylin alongside nutritional support in certain patient populations.


Q: Is Cylin approved for use in patients with a history of heart problems?

Official product information advises using Cylin with caution in patients who have a history of cardiovascular disease or hypertension (high blood pressure). This caution is related to the potential for effects such as tachycardia (an increased heart rate).


Q: Does Cylin carry a risk of dependence or withdrawal symptoms?

Regulatory documents do not state a risk of drug dependence. However, withdrawal symptoms, such as headache, nausea, or anxiety, have been reported upon stopping certain sedating antihistamines, and some literature describes gradual discontinuation.


Q: What are the general expectations for a patient starting Cylin?

Patients beginning Cylin should expect its intended function is to help relieve allergic symptoms or stimulate appetite, depending on its prescribed use. Official documents emphasize that drowsiness is a very common initial side effect that may diminish. Patients are generally advised to avoid operating heavy machinery until they understand the medication's full impact.


Q: What happens if a dose of Cylin is missed?

The official administration instruction is a procedural one: if a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped entirely. The instruction is that the dose should not be doubled. The regulatory label does not describe the specific clinical effects or risks of missing a dose.


Q: Is Cylin used for other conditions besides its main approved use?

In addition to treating allergic conditions and providing appetite stimulation, official regulatory documents in some regions also list the use of Cylin for the prevention of recurrent vascular headaches (migraine prophylaxis). The medication's specific uses are defined by the regulatory approvals in each region.


Q: Is Cylin an expensive medication?

The availability of generic formulations of Cyproheptadine hydrochloride means that patients have access to lower-cost alternatives to the brand name Cylin. The actual cost to the patient will depend on the specific formulation purchased, dosage, and insurance coverage.


Q: Can Cylin be used during pregnancy or while breastfeeding?

The FDA Pregnancy Category for Cylin is Category B. While reproduction studies in animals and two human studies did not show an increased risk of abnormalities, official information states it should only be used during pregnancy if clearly needed. Use is contraindicated (prohibited) in nursing mothers due to the potential for adverse reactions in infants. This information helps guide appropriate patient selection.

How should Cylin be stored and disposed of?

Official Storage and Disposal Requirements

Storage Category Official Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C, allowing for brief excursions between 15 C and 30 C.
Protection & Handling Keep the medicine in its original, tightly closed container. Protect from both light and moisture. Do not use the medication past the expiration date printed on the container.
Child Safety To prevent accidental ingestion, keep this medicine out of the sight and reach of children and store it in a secure location.
Disposal Do not dispose of unused Cylin in household trash or flush it down the toilet unless explicitly instructed by a government authority. Instead, follow local regulations by using an authorized drug take-back program or returning it to a pharmacy for proper disposal.

These requirements, established in official regulatory documents, ensure the medication maintains its quality and strength until its expiration date and mitigate public safety risks during its disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cylin found in:

A-Z Index: